Morbidity and Mortality after Induction Chemotherapy Followed by Surgery in IIIa-N2 non Small Cell Lung Cancer

被引:1
|
作者
Borreman, Ph. [1 ]
De Leyn, P. [1 ]
Decaluwe, H. [1 ]
Moons, J. [1 ]
Van Raemdonck, D. [1 ]
Nafteux, Ph. [1 ]
Coosemans, W. [1 ]
Lerut, T. [1 ]
机构
[1] Katholieke Univ Leuven Hosp, Dept Thorac Surg, Louvain, Belgium
关键词
Lung cancer; non-small-cell carcinoma; chemotherapy; adjuvant; pneumonectomy; PROLONGED AIR LEAK; PREOPERATIVE CHEMOTHERAPY; PULMONARY LOBECTOMY; COMORBIDITY SCORE; RESECTION; COMPLICATIONS; SYSTEM; PREDICTORS; THERAPY; POSSUM;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective : To evaluate the frequency and risk of postoperative complications and mortality in patients with IIIa-N2 non small cell lung cancer after induction chemotherapy and surgery. Methods : In a surgical database records from ninety two patients, operated between January 1, 2000 and December 3 1, 2006 were reviewed. Univariate analysis was used to identify predictors of postoperative complications and in-hospital mortality. Results : All cases were histologically confirmed stage IIIa-N2. All patients received preoperative platinum based chemotherapy without radiotherapy. Pneumonectomy was performed in 20 cases (23.5%), from which 9 right sided. (Bi)lobectomy was performed in 53 cases (62.4%) and sleeve lobectomy in I I cases (17.2%). One wedge resection was performed (1.2%). In 7 cases (7.6%) only an exploration was done. Complications developed in 35 patients (38%). Major complications in 15 patients (16%). No bronchopleural fistulae were observed. Analysis identified increased age and high physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) as a risk factor to develop complications, and a high simplified comorbidity score as a risk factor to develop a major complication. Higher age, Charlson comorbidity index, simplified comorbidity score and POSSUM were a risk factor for developing pneumonia. Conclusion : Although surgery after induction therapy for IIIa-N2 NSCLC can be done with a morbidity and mortality comparable to surgery alone, it remains a high risk operation. It should therefore be performed in a center with experience. Bronchial stump protection should be used whenever there is an increased risk for developing a bronchopleural fistula. In deciding whether to do surgery or radiotherapy one should keep in mind the feasibility of performing a complete resection together with a preoperative assessment to predict complications and mortality. For the preoperative assessment several scoring systems can be used from which we find the simplified comorbidity score most useful.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [21] ASO Author Reflections: Upfront Surgery Followed by Adjuvant Therapy: An Option for IIIA-N2 Non-small Cell Lung Cancer
    Fangqiu Fu
    Yang Zhang
    Haiquan Chen
    Annals of Surgical Oncology, 2023, 30 : 8284 - 8284
  • [22] Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer
    Van Meerbeeck, Jan P.
    Van Schil, Paul E. Y.
    Senan, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (12) : 1138 - 1139
  • [23] Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!
    Berzenji, Lawek
    Beckers, Paul
    Van Schil, Paul E.
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1153 - S1156
  • [24] Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer
    Lee, Hyun Woo
    Noh, O. Kyu
    Oh, Young-Taek
    Choi, Jin-Hyuk
    Chun, Mison
    Kim, Hwan-Ik
    Heo, Jaesung
    Ahn, Mi Sun
    Park, Seong Yong
    Park, Rae Woong
    Yoon, Dukyong
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (03): : 621 - 627
  • [25] Tumor size as a predictor for prognosis of patients with surgical IIIA-N2 non-small cell lung cancer after surgery
    Zhang, Kunpeng
    Cai, Jiahao
    Lu, Chunlai
    Zhu, Qiaoliang
    Zhan, Cheng
    Shen, Yaxing
    Gu, Jie
    Ge, Di
    JOURNAL OF THORACIC DISEASE, 2021, 13 (07) : 4114 - 4124
  • [26] Neoadjuvant strategy for stage IIIA-N2 non-small cell lung cancer: chemoradiation or chemotherapy alone?
    Situ, Dongrong
    Lin, Yongbin
    JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2746 - 2748
  • [27] Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: A review
    Vansteenkiste, J
    De Leyn, P
    Deneffe, G
    Menten, J
    Lerut, T
    Demedts, M
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1998, 13 (01) : 1 - 12
  • [28] A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically-Proven Clinical IIIA-N2 Non-Small Cell Lung Cancer
    Yokomise, Hiroyasu
    Tanaka, Fumihiro
    Soejima, Toshinori
    Uramoto, Hidetaka
    Yamanaka, Takeharu
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Nishimura, Yasumasa
    Niwa, Hiroshi
    Okada, Morihito
    Nakagawa, Tatsuo
    Yamashita, Motohiro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1094 - S1095
  • [29] Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer - Response
    Van Schil, P.
    Van Meerbeeck, J.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (15) : 1210 - 1211
  • [30] Recurrence Dynamics After Complete Resection and Adjuvant Chemotherapy in Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer
    Sun, X.
    Men, Y.
    Yang, X.
    Deng, L.
    Wang, W.
    Zhai, Y. R.
    Liu, W., Jr.
    Zhang, T.
    Wang, X.
    Bi, N.
    Lv, J.
    Liang, J.
    Feng, Q.
    Chen, D.
    Xiao, Z.
    Zhou, Z.
    Wang, L.
    Hui, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E453 - E453